Atara Biotherapeutics, Inc.
ATRA
$14.02
$1.4711.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 151.93M | 188.67M | 199.73M | 128.94M | 100.44M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 151.93M | 188.67M | 199.73M | 128.94M | 100.44M |
| Cost of Revenue | 78.62M | 127.12M | 131.19M | 135.77M | 147.39M |
| Gross Profit | 73.31M | 61.55M | 68.54M | -6.83M | -46.95M |
| SG&A Expenses | 29.36M | 35.81M | 38.78M | 38.53M | 39.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 114.35M | 169.29M | 202.95M | 207.27M | 219.84M |
| Operating Income | 37.59M | 19.38M | -3.22M | -78.33M | -119.41M |
| Income Before Tax | 23.41M | 5.76M | -15.68M | -85.42M | -133.14M |
| Income Tax Expenses | 12.00K | -33.00K | -36.00K | -12.00K | 18.00K |
| Earnings from Continuing Operations | 23.40 | 5.80 | -15.64 | -85.40 | -133.16 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.40M | 5.80M | -15.64M | -85.40M | -133.16M |
| EBIT | 37.59M | 19.38M | -3.22M | -78.33M | -119.41M |
| EBITDA | 41.73M | 24.88M | 2.24M | -73.28M | -114.25M |
| EPS Basic | 2.22 | -0.39 | -3.69 | -12.87 | -25.66 |
| Normalized Basic EPS | 2.04 | 0.40 | -1.70 | -7.48 | -14.50 |
| EPS Diluted | 2.18 | -0.43 | -3.72 | -12.87 | -25.66 |
| Normalized Diluted EPS | 2.02 | 0.38 | -1.72 | -7.48 | -14.50 |
| Average Basic Shares Outstanding | 47.24M | 41.14M | 35.08M | 29.94M | 23.56M |
| Average Diluted Shares Outstanding | 47.44M | 41.34M | 35.17M | 29.94M | 23.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |